Price T Rowe Associates Inc Aquestive Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 23,848 shares of AQST stock, worth $115,424. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,848Holding current value
$115,424% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AQST
# of Institutions
98Shares Held
42.7MCall Options Held
271KPut Options Held
212K-
Bratton Capital Management, L.P. Fort Worth, TX9.81MShares$47.5 Million100.0% of portfolio
-
Vr Adviser, LLC New York, NY5.56MShares$26.9 Million1.58% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$26.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.23MShares$20.5 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA2.85MShares$13.8 Million0.0% of portfolio
About Aquestive Therapeutics, Inc.
- Ticker AQST
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,350,700
- Market Cap $258M
- Description
- Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...